{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:14:05Z","timestamp":1783498445850,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100018627","name":"Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China","doi-asserted-by":"publisher","award":["21Y31920300\uff0c21Y31920304"],"award-info":[{"award-number":["21Y31920300\uff0c21Y31920304"]}],"id":[{"id":"10.13039\/501100018627","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00415-026-13910-1","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T15:56:43Z","timestamp":1781452603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination therapy of levodopa with safinamide is more effective than with rasagiline and zonisamide in Asian Parkinson\u2019s disease patients with motor fluctuations: a systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"273","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Ji","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Huang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duan-Lu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Jia","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng-King","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4581-6524","authenticated-orcid":false,"given":"Yun-Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,14]]},"reference":[{"issue":"4","key":"13910_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"JD Steinmetz","year":"2024","unstructured":"Steinmetz JD et al (2024) Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Lancet Neurol 23(4):344\u2013381","journal-title":"Lancet Neurol"},{"issue":"1","key":"13910_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40801-023-00410-1","volume":"11","author":"KR Chaudhuri","year":"2024","unstructured":"Chaudhuri KR et al (2024) Economic Burden of Parkinson\u2019s Disease: a multinational, real-world, cost-of-illness study. Drugs Real World Outcomes 11(1):1\u201311","journal-title":"Drugs Real World Outcomes"},{"issue":"8","key":"13910_CR3","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","volume":"16","author":"N Tambasco","year":"2018","unstructured":"Tambasco N, Romoli M, Calabresi P (2018) Levodopa in Parkinson\u2019s disease: current status and future developments. Curr Neuropharmacol 16(8):1239\u20131252","journal-title":"Curr Neuropharmacol"},{"key":"13910_CR4","doi-asserted-by":"publisher","DOI":"10.1042\/BST20231061","author":"MDS Tai","year":"2024","unstructured":"Tai MDS, Gamiz-Arco G, Martinez A (2024) Dopamine synthesis and transport: current and novel therapeutics for parkinsonisms. Biochem Soc Trans. https:\/\/doi.org\/10.1042\/BST20231061","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"13910_CR5","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s13311-020-00889-4","volume":"17","author":"SD Aradi","year":"2020","unstructured":"Aradi SD, Hauser RA (2020) Medical management and prevention of motor complications in Parkinson\u2019s disease. Neurotherapeutics 17(4):1339\u20131365","journal-title":"Neurotherapeutics"},{"issue":"1","key":"13910_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mds.27882","volume":"35","author":"HJ Kim","year":"2020","unstructured":"Kim HJ et al (2020) Motor complications in Parkinson\u2019s disease: 13-year follow-up of the CamPaIGN cohort. Mov Disord 35(1):185\u2013190","journal-title":"Mov Disord"},{"key":"13910_CR7","first-page":"719167","volume":"2012","author":"SD Vassar","year":"2012","unstructured":"Vassar SD et al (2012) Confirmatory factor analysis of the motor unified Parkinson\u2019s disease rating scale. Parkinsons Dis 2012:719167","journal-title":"Parkinsons Dis"},{"issue":"2","key":"13910_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3233\/JPD-212976","volume":"12","author":"Y-Y Tan","year":"2022","unstructured":"Tan Y-Y, Jenner P, Chen S-D (2022) Monoamine oxidase-B inhibitors for the treatment of Parkinson\u2019s disease: past, present, and future. J Parkinsons Dis 12(2):477\u2013493","journal-title":"J Parkinsons Dis"},{"issue":"4","key":"13910_CR9","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/ene.15651","volume":"30","author":"R Yan","year":"2023","unstructured":"Yan R et al (2023) Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson\u2019s disease: a network meta-analysis of randomized controlled trials. Eur J Neurol 30(4):1118\u20131134","journal-title":"Eur J Neurol"},{"issue":"11","key":"13910_CR10","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s40263-023-01048-x","volume":"37","author":"L Aboulatta","year":"2023","unstructured":"Aboulatta L et al (2023) Efficacy and safety of MAO-B inhibitors safinamide and zonisamide in Parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs 37(11):941\u2013956","journal-title":"CNS Drugs"},{"issue":"1","key":"13910_CR11","doi-asserted-by":"publisher","first-page":"10502","DOI":"10.1038\/s41598-025-94960-9","volume":"15","author":"Y Tan","year":"2025","unstructured":"Tan Y et al (2025) Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson\u2019s disease patients with a matching adjusted indirect comparison. Sci Rep 15(1):10502","journal-title":"Sci Rep"},{"key":"13910_CR12","doi-asserted-by":"publisher","DOI":"10.1101\/2025.07.08.25330815","author":"LM Lange","year":"2025","unstructured":"Lange LM et al (2025) The global landscape of genetic variation in Parkinson\u2019s disease multi ancestry insights into established disease genes and their translational relevance. medRxiv. https:\/\/doi.org\/10.1101\/2025.07.08.25330815","journal-title":"medRxiv"},{"issue":"3","key":"13910_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.stem.2011.01.013","volume":"8","author":"HN Nguyen","year":"2011","unstructured":"Nguyen HN et al (2011) LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8(3):267\u2013280","journal-title":"Cell Stem Cell"},{"key":"13910_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911059","author":"M Naoi","year":"2022","unstructured":"Naoi M, Maruyama W, Shamoto-Nagai M (2022) Neuroprotective function of rasagiline and selegiline, inhibitors of type B monoamine oxidase, and role of monoamine oxidases in synucleinopathies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms231911059","journal-title":"Int J Mol Sci"},{"issue":"5","key":"13910_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ana.10191","volume":"51","author":"I Shoulson","year":"2002","unstructured":"Shoulson I et al (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson\u2019s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51(5):604\u2013612","journal-title":"Ann Neurol"},{"issue":"4","key":"13910_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mds.20036","volume":"19","author":"CH Waters","year":"2004","unstructured":"Waters CH et al (2004) Zydis selegiline reduces off time in Parkinson\u2019s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 19(4):426\u2013432","journal-title":"Mov Disord"},{"key":"13910_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1134472","volume":"15","author":"K Wang","year":"2023","unstructured":"Wang K et al (2023) Efficacy and safety of selegiline for the treatment of Parkinson\u2019s disease: a systematic review and meta-analysis. Front Aging Neurosci 15:1134472","journal-title":"Front Aging Neurosci"},{"issue":"11","key":"13910_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"key":"13910_CR19","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions, version 6.4 (updated August 2023)","author":"J Higgins","year":"2023","unstructured":"Higgins J et al (2023) Cochrane Handbook for Systematic Reviews of Interventions, version 6.4 (updated August 2023). Cochrane, London, UK"},{"key":"13910_CR20","volume-title":"XADAGO\u00ae(safinamide) tablets, prescribing information","author":"Zambon","year":"2017","unstructured":"Zambon (2017) XADAGO\u00ae(safinamide) tablets, prescribing information. FDA"},{"key":"13910_CR21","volume-title":"Rasagiline tablets prescribing information","author":"M.P., Inc.","year":"2006","unstructured":"M.P., Inc. (2006) Rasagiline tablets prescribing information. FDA"},{"key":"13910_CR22","volume-title":"Zonisamide tablets, prescribing information","author":"Sumitomo Pharma Co., L.","year":"2023","unstructured":"Sumitomo Pharma Co., L. (2023) Zonisamide tablets, prescribing information. PMDA (Pharmaceuticals and Medical Devices Agency)"},{"issue":"5","key":"13910_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S et al (2013) Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33(5):641\u2013656","journal-title":"Med Decis Making"},{"issue":"1","key":"13910_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","volume":"6","author":"L Mbuagbaw","year":"2017","unstructured":"Mbuagbaw L et al (2017) Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev 6(1):79","journal-title":"Syst Rev"},{"issue":"11","key":"13910_CR25","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40263-022-00958-6","volume":"36","author":"Q Wei","year":"2022","unstructured":"Wei Q et al (2022) The XINDI study: a randomized phase III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in Chinese patients with Parkinson\u2019s disease with motor fluctuations. CNS Drugs 36(11):1217\u20131227","journal-title":"CNS Drugs"},{"issue":"2","key":"13910_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.14802\/jmd.22196","volume":"16","author":"R Bhidayasiri","year":"2023","unstructured":"Bhidayasiri R et al (2023) Safinamide as an adjunct to levodopa in Asian and Caucasian patients with Parkinson\u2019s disease and motor fluctuations: a post hoc analysis of the SETTLE study. J Mov Disord 16(2):180","journal-title":"J Mov Disord"},{"key":"13910_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","volume":"75","author":"N Hattori","year":"2020","unstructured":"Hattori N et al (2020) Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled, phase II\/III study. Parkinsonism Relat Disord 75:17\u201323","journal-title":"Parkinsonism Relat Disord"},{"key":"13910_CR28","first-page":"1","volume":"7","author":"Z Zhang","year":"2018","unstructured":"Zhang Z et al (2018) Adjunct rasagiline to treat Parkinson\u2019s disease with motor fluctuations: a randomized, double-blind study in China. Transl Neurodegener 7:1\u201311","journal-title":"Transl Neurodegener"},{"key":"13910_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.parkreldis.2018.04.025","volume":"53","author":"N Hattori","year":"2018","unstructured":"Hattori N et al (2018) Efficacy and safety of adjunctive rasagiline in Japanese Parkinson\u2019s disease patients with wearing-off phenomena: a phase 2\/3, randomized, double-blind, placebo-controlled, multicenter study. Parkinsonism Relat Disord 53:21\u201327","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"13910_CR30","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1017\/S1461145713000175","volume":"16","author":"L Zhang","year":"2013","unstructured":"Zhang L et al (2013) Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson\u2019s disease: a randomized, double-blind, parallel-controlled, multi-centre trial. Int J Neuropsychopharmacol 16(7):1529\u20131537","journal-title":"Int J Neuropsychopharmacol"},{"key":"13910_CR31","unstructured":"A\/S, H.L., Study of Azilect\u00ae (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea. ClinicalTrials.gov ID: NCT01268891, 2013"},{"issue":"12","key":"13910_CR32","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1001\/jamaneurol.2015.2268","volume":"72","author":"RA Hauser","year":"2015","unstructured":"Hauser RA et al (2015) Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned. JAMA Neurol 72(12):1491\u20131500","journal-title":"JAMA Neurol"},{"issue":"10","key":"13910_CR33","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/mds.26286","volume":"30","author":"M Murata","year":"2015","unstructured":"Murata M et al (2015) Zonisamide improves wearing-off in Parkinson\u2019s disease: a randomized, double-blind study. Mov Disord 30(10):1343\u20131350","journal-title":"Mov Disord"},{"issue":"1","key":"13910_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","volume":"68","author":"M Murata","year":"2007","unstructured":"Murata M et al (2007) Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68(1):45\u201350","journal-title":"Neurology"},{"issue":"1","key":"13910_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/ncn3.12026","volume":"4","author":"M Murata","year":"2016","unstructured":"Murata M et al (2016) Randomized placebo-controlled trial of zonisamide in patients with Parkinson\u2019s disease. Neurol Clin Neurosci 4(1):10\u201315","journal-title":"Neurol Clin Neurosci"},{"issue":"9","key":"13910_CR36","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1111\/bcp.13651","volume":"84","author":"CD Binde","year":"2018","unstructured":"Binde CD et al (2018) A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson\u2019s disease. Br J Clin Pharmacol 84(9):1917\u20131927","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"13910_CR37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00415-025-13230-w","volume":"272","author":"MB Khalid","year":"2025","unstructured":"Khalid MB et al (2025) Comparative efficacy and safety of irreversible (rasagiline) and reversible (safinamide) monoamine oxidase inhibitors as add-on therapy for Parkinson\u2019s disease. J Neurol 272(7):486","journal-title":"J Neurol"},{"key":"13910_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/9781118951651","volume-title":"Network meta-analysis for decision-making","author":"S Dias","year":"2018","unstructured":"Dias S et al (2018) Network meta-analysis for decision-making. John Wiley & Sons"},{"issue":"4","key":"13910_CR39","first-page":"116","volume":"3","author":"Y-C Wu","year":"2022","unstructured":"Wu Y-C, Tu Y-K (2022) High robustness does not always imply low uncertainty of treatment rankings: an empirical study of 60 network meta-analyses. Res Methods Med Health Sci 3(4):116\u2013120","journal-title":"Res Methods Med Health Sci"},{"issue":"5\u20136","key":"13910_CR40","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00702-022-02465-w","volume":"129","author":"WH Jost","year":"2022","unstructured":"Jost WH (2022) A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease. J Neural Transm (Vienna) 129(5\u20136):723\u2013736","journal-title":"J Neural Transm (Vienna)"},{"key":"13910_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2024.115410","volume":"480","author":"X Liu","year":"2025","unstructured":"Liu X et al (2025) Effects of MAO-B inhibitors in life quality of Parkinson\u2019s disease patients: a systematic review and meta-analysis. Behav Brain Res 480:115410","journal-title":"Behav Brain Res"},{"key":"13910_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107103","volume":"127","author":"R Bovenzi","year":"2024","unstructured":"Bovenzi R et al (2024) Safinamide effect on sleep architecture of motor fluctuating Parkinson\u2019s disease patients: a polysomnographic rasagiline-controlled study. Parkinsonism Relat Disord 127:107103","journal-title":"Parkinsonism Relat Disord"},{"key":"13910_CR43","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e213","author":"H-S Kim","year":"2018","unstructured":"Kim H-S, Lee S, Kim JH (2018) Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. https:\/\/doi.org\/10.3346\/jkms.2018.33.e213","journal-title":"J Korean Med Sci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13910-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13910-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13910-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:21:13Z","timestamp":1783495273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13910-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,14]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["13910"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13910-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,14]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We declare no competing interests for all authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"396"}}